Singapore markets closed

ADTX Jan 2024 3.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
2.85000.0000 (0.00%)
As of 08:49AM EST. Market open.
Full screen
Previous close2.8500
Open2.8500
Bid1.0000
Ask5.4000
Strike3.00
Expiry date2024-01-19
Day's range2.8500 - 2.8500
Contract rangeN/A
Volume1
Open interest4
  • Business Wire

    Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform

    MOUNTAIN VIEW, Calif., October 05, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation activation company focused on the discovery, development, and deployment of technologies that monitor and modulate the immune system, announced today that it has appointed Ernie Lee to serve as the Chief Executive Officer of the Company’s wholly-owned subsidiary Pearsanta, Inc. ("Pearsanta"). Ernie’s appointment is intended to accelerate the commercial launch of Test2Treat.me. T

  • Business Wire

    Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023

    RICHMOND, Va. & MOUNTAIN VIEW, Calif., September 08, 2023--Aditxt,® Inc, (NASDAQ: ADTX) ("Aditxt" or the "Company"), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel

  • Business Wire

    Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

    RICHMOND, Va., September 06, 2023--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrants in lieu thereof) an